Protocol assesses antiviral activity against SARS-CoV-2 using iPSC pneumocyte cells, indicating drug efficacy and toxicity.
The following is a protocol for live virus antiviral screening against SARS-CoV-2 in iPSC pneumocyte cells. iPSC pneumocytes are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against SARS-CoV-2. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Briana L McGovern (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: